You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Targeting lipid rafts for treatment of migraine

    SBC: RAFT PHARMACEUTICALS LLC            Topic: NINDS

    PROJECT SUMMARY Migraine is a highly prevalent condition with an extraordinarily negative impact on quality of life and represents a heavy socioeconomic burden to the societyprimarily because of decreased working efficiency and workdays lostManagement of migraine has become increasingly pharmacological during recent yearsWhile several therapeutic options existmost of the prophylactic drugs current ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Novel monoclonal antibody for single dose treatment of acute CNS injury

    SBC: OncoSynergy, Inc.            Topic: NINDS

    PROJECT SUMMARY Traumatic brain injuryTBIrepresents a significant societal and economic impactTo datethere are no FDAapproved pharmacotherapies to prevent or reverse TBIThe standard of care in an emergency setting focuses first on stabilizing the patient and secondly on management of cerebral hemodynamicsThe patient may undergo surgery to remove hematomasrepair skull fracturesand relieve intracran ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Pre-clinical evaluation of DT-001, a small molecule antagonist of MD2-TLR4 for utility in the treatment of pain.

    SBC: Douleur Therapeutics Inc            Topic: NINDS

    Project Summary AbstractUpwards ofmillion individuals are afflicted by chronic pain in the US alonewithmillion of these individuals suffering from neuropathic painOn a global scalechronic pain affectsbillion individualswithwho endure lower back painFrom a clinical perspectivethe International Association for the Study of Pain approximates thatinpatients present with painand on an annual basisinpat ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    Filovirusesconsisting of two major virus families including the ebolaviruses and marburgvirusesMARV and RAVVcause periodic outbreaks of severe viral hemorrhagic fever with mortality rates as high asSince it is difficult to predict the species that would dominate future outbreaksdevelopment of broadly protective therapeutics to prevent and manage future filovirus outbreaks is of high priorityIn sha ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. NOVO-118 as a therapeutic to promote remyelination in in vivo models of MS

    SBC: Novoron Bioscience Inc.            Topic: NINDS

    Project Summary Multiple sclerosisMSis a neurodegenerative disease in which myelin of the central nervous systemCNSis destroyed by a self reactive immune responseThis demyelination is accompanied by the death of the myelinating cells themselvesthe oligodendrocytesRepeated bouts of demyelination leave the denuded CNS neurons vulnerable to degradation and is the major cause of neuronal dysfunction a ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Targeting lipid rafts for treatment of asthma

    SBC: RAFT PHARMACEUTICALS LLC            Topic: NIAID

    PROJECT SUMMARY Asthmacharacterized by airways obstruction with symptoms of wheezingshortness of breathchest tightness and consequently coughremains a significant health problemWhile advances in bronchodilatorcorticosteroid and Thtargeting therapy allow for well controlled asthma in a large population of patientssubjects with severecorticosteroid resistant asthma require frequent hospitalizations ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Custom-Fit Personal Sound Amplification Smartphone Application

    SBC: ASCENDING HEARING TECHNOLOGIES, LLC            Topic: NIDCD

    PROJECT SUMMARYPersonal sound amplification productsPSAPshave recently become available to the publicPSAPs serve a potentially important role in providing audibility of sounds for adults who have difficulty hearing in some daily living situationsbut may not be candidates for traditionalhigh amplification hearing aidsFewer thanof adults with hearing loss reporting use of hearing aidsciting high cos ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. A novel asthma drug candidate targeting the GABAergic system in lung inflammation

    SBC: PANTHERICS INCORPORATED            Topic: NHLBI

    The proposed research will advance preclinical characterization and validation of a novel drug for asthmaA growing body of research has uncovered functional gamma amino butyric acid type A receptorGABAARsignaling in non neuronal cellsOur research has demonstrated that ligands activating GABAAR subtypes located on airway smooth muscle and immune cells reduce airway hyper responsivenessAHRand inflam ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT TypeDiabetes MellitusT DMaffectsmillion patients in US withnew patients annuallyLifespan is shortenedyearsdue to kidney and heart diseaseTight glucose control reduces microvascular complications and adverse cardiovascular eventsInsulin therapy is essential for such patientsbut has shortcomingsaonlyinpatients achieve targeted glucose controlHbA c andltbaggressive insulin therapy increases ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. High-Throughput Assay for Profiling Alternative Splicing and Splicing Regulators

    SBC: BioSpyder Technologies, Inc.            Topic: 172

    SummaryThis Phase I program will develop TempO Splicea highly multiplexed targeted sequencing assay monitoring RNA Binding ProteinRBPsplicing expression and alternatively splicedASmRNA representatives of coregulated splicing modulesa novel variation of the TempO Seqassay used for high throughput screeningdesigned to address the hypothesis that it is possible to provide a surrogate assay of the who ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government